A testosterone metabolite 19-hydroxyandrostenedione induces neuroendocrine trans-differentiation of prostate cancer cells via an ectopic olfactory receptor

Frontiers in Oncology

Volumn 8, Issue MAY, 2018, Pages

  Abaffy, Tatjana ^a   Bain, James R ^b   Muehlbauer, Michael J ^b   Spasojevic, Ivan ^b   Lodha, Shweta ^b   Bruguera, Elisa ^b   O'Neal, Sara K ^b   Kim, So Young ^b   Matsunami, Hiroaki ^b  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

19 hydroxyandrostenedione; Agonists; Neuroendocrine trans differentiation; Neuron specific enolase; Olfactory receptor; OR51E2; Prostate cancer; PSGR

Indexed keywords

19 HYDROXYANDROSTENEDIONE; BIOLOGICAL MARKER; TESTOSTERONE;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; COMPUTER MODEL; GENE KNOCKOUT; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LUCIFERASE ASSAY; METABOLITE; METABOLOMICS; NEUROENDOCRINE TUMOR; NONHUMAN; OLFACTORY RECEPTOR; PHENOTYPE; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; TUMOR DIFFERENTIATION;

EID: 85047660018     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2018.00162     Document Type: Article

References (84)

1. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer (2007) 7(2):79-94. doi:10.1038/nrc2069
2. Julius D, Livelli TJ, Jessell TM, Axel R. Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science (1989) 244(4908):1057-62. doi:10.1126/science.2727693
3. Gutkind JS, Novotny EA, Brann MR, Robbins KC. Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci U S A (1991) 88(11):4703-7. doi:10.1073/pnas.88.11.4703
4. Allen LF, Lefkowitz RJ, Caron MG, Cotecchia S. G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc Natl Acad Sci U S A (1991) 88(24):11354-8. doi:10.1073/pnas.88.24.11354
5. Gutkind JS. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene (1998) 17(11 Reviews):1331-42. doi:10.1038/sj.onc.1202186
6. O'Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol (2014) 27:126-35. doi:10.1016/j.ceb.2014.01.005
7. Abaffy T. Human olfactory receptors expression and their role in non-olfactory tissues-a mini review. J Pharmacogenomics Pharmacoproteomics (2015) 6(4):152. doi:10.4172/2153-0645.1000152
8. Spehr M, Gisselmann G, Poplawski A, Riffell JA, Wetzel CH, Zimmer RK, et al. Identification of a testicular odorant receptor mediating human sperm chemotaxis. Science (2003) 299(5615):2054-8. doi:10.1126/science.1080376
9. Pavlath GK. A new function for odorant receptors: MOR23 is necessary for normal tissue repair in skeletal muscle. Cell Adh Migr (2010) 4(4):502-6. doi:10.4161/cam.4.4.12291
10. Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A (2013) 110(11):4410-5. doi:10.1073/pnas.1215927110
11. Chang AJ, Ortega FE, Riegler J, Madison DV, Krasnow MA. Oxygen regulation of breathing through an olfactory receptor activated by lactate. Nature (2015) 527(7577):240-4. doi:10.1038/nature15721
12. Flegel C, Manteniotis S, Osthold S, Hatt H, Gisselmann G. Expression profile of ectopic olfactory receptors determined by deep sequencing. PLoS One (2013) 8(2):e55368. doi:10.1371/journal.pone.0055368
13. Niimura Y, Matsui A, Touhara K. Extreme expansion of the olfactory receptor gene repertoire in African elephants and evolutionary dynamics of orthologous gene groups in 13 placental mammals. Genome Res (2014) 24(9):1485-96. doi:10.1101/gr.169532.113
14. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, et al. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res (2000) 60(23):6568-72
15. Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, et al. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis (2006) 9(1):56-61. doi:10.1038/sj.pcan.4500836
16. Weng J, Wang J, Cai Y, Stafford LJ, Mitchell D, Ittmann M, et al. Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int J Cancer (2005) 113(5):811-8. doi:10.1002/ijc.20635
17. Xia C, Ma W, Wang F, Hua SB, Liu M. Identification of a prostate-specific G-protein coupled receptor in prostate cancer. Oncogene (2001) 20(41):5903-7. doi:10.1038/sj.onc.1204803
18. Vaarala MH, Hirvikoski P, Kauppila S, Paavonen TK. Identification of androgen-regulated genes in human prostate. Mol Med Rep (2012) 6(3):466-72. doi:10.3892/mmr.2012.956
19. Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res (2004) 64(17):5963-72. doi:10.1158/0008-5472.CAN-04-0020
20. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett (2006) 236(2):229-38. doi:10.1016/j.canlet.2005.05.021
21. Weigle B, Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, et al. D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochem Biophys Res Commun (2004) 322(1):239-49. doi:10.1016/j.bbrc.2004.07.106
22. Rodriguez M, Siwko S, Liu M. Prostate-specific G-protein coupled receptor, an emerging biomarker regulating inflammation and prostate cancer invasion. Curr Mol Med (2016) 16(6):526-32. doi:10.2174/1566524016666160607091333
23. Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol (2015) 5:90. doi:10.3389/fonc.2015.00090
24. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol (2009) 16(1):37-44. doi:10.1111/j.1442-2042.2008.02175.x
25. Farach A, Ding Y, Lee M, Creighton C, Delk NA, Ittmann M, et al. Neuronal trans-differentiation in prostate cancer cells. Prostate (2016) 76(14):1312-25. doi:10.1002/pros.23221
26. Firestein S. How the olfactory system makes sense of scents. Nature (2001) 413(6852):211-8. doi:10.1038/35093026
27. Massberg D, Simon A, Haussinger D, Keitel V, Gisselmann G, Conrad H, et al. Monoterpene (-)-citronellal affects hepatocarcinoma cell signaling via an olfactory receptor. Arch Biochem Biophys (2015) 566:100-9. doi:10.1016/j.abb.2014.12.004
28. Manteniotis S, Wojcik S, Brauhoff P, Mollmann M, Petersen L, Gothert JR, et al. Functional characterization of the ectopically expressed olfactory receptor 2AT4 in human myelogenous leukemia. Cell Death Discov (2016) 2:15070. doi:10.1038/cddiscovery.2015.70
29. Gelis L, Jovancevic N, Veitinger S, Mandal B, Arndt HD, Neuhaus EM, et al. Functional characterization of the odorant receptor 51E2 in human melanocytes. J Biol Chem (2016) 291(34):17772-86. doi:10.1074/jbc.M116.734517
30. Rodriguez M, Siwko S, Zeng L, Li J, Yi Z, Liu M. Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression. Oncogene (2016) 35(9):1153-62. doi:10.1038/onc.2015.170
31. Neuhaus EM, Zhang W, Gelis L, Deng Y, Noldus J, Hatt H. Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem (2009) 284(24):16218-25. doi:10.1074/jbc.M109.012096
32. Sanz G, Leray I, Dewaele A, Sobilo J, Lerondel S, Bouet S, et al. Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation. PLoS One (2014) 9(1):e85110. doi:10.1371/journal.pone.0085110
33. Cao W, Li F, Yao J, Yu J. Prostate specific G protein coupled receptor is associated with prostate cancer prognosis and affects cancer cell proliferation and invasion. BMC Cancer (2015) 15:915. doi:10.1186/s12885-015-1921-6
34. Saito H, Chi Q, Zhuang H, Matsunami H, Mainland JD. Odor coding by a mammalian receptor repertoire. Sci Signal (2009) 2(60):ra9. doi:10.1126/scisignal.2000016
35. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol (1993) 234(3):779-815. doi:10.1006/jmbi.1993.1626
36. Shen MY, Sali A. Statistical potential for assessment and prediction of protein structures. Protein Sci (2006) 15(11):2507-24. doi:10.1110/ps.062416606
37. Abagyan R, Totrov M, Kuznetsov D. ICM-A new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J Comput Chem (1994) 15(5):488-506. doi:10.1002/jcc.540150503
38. Bavan S, Sherman B, Luetje CW, Abaffy T. Discovery of novel ligands for mouse olfactory receptor MOR42-3 using an in silico screening approach and in vitro validation. PLoS One (2014) 9(3):e92064. doi:10.1371/journal.pone.0092064
39. Abaffy T, Malhotra A, Luetje CW. The molecular basis for ligand specificity in a mouse olfactory receptor-a network of functionally important residues. J Biol Chem (2007) 282(2):1216-24. doi:10.1074/jbc.M609355200
40. Neves MAC, Totrov M, Abagyan R. Docking and scoring with ICM: the benchmarking results and strategies for improvement. J Comput Aided Mol Des (2012) 26(6):675-86. doi:10.1007/s10822-012-9547-0
41. Rege J, Nakamura Y, Satoh F, Morimoto R, Kennedy MR, Layman LC, et al. Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. J Clin Endocrinol Metab (2013) 98(3):1182-8. doi:10.1210/jc.2012-2912
42. Halket JM, Przyborowska A, Stein SE, Mallard WG, Down S, Chalmers RA. Deconvolution gas chromatography/mass spectrometry of urinary organic acids-potential for pattern recognition and automated identification of metabolic disorders. Rapid Commun Mass Spectrom (1999) 13(4):279-84. doi:10.1002/(SICI)1097-0231(19990228)13:4<279::AID-RCM478>3.0.CO;2-I
43. Kind T, Wohlgemuth G, Lee DY, Lu Y, Palazoglu M, Shahbaz S, et al. FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal Chem (2009) 81(24):10038-48. doi:10.1021/ac9019522
44. Xia J, Wishart DS. Using metaboanalyst 3.0 for comprehensive metabolomics data analysis. Curr Protoc Bioinformatics (2016) 55:14.10.1-14.10.91. doi:10.1002/cpbi.11
45. Zhuang H, Matsunami H. Evaluating cell-surface expression and measuring activation of mammalian odorant receptors in heterologous cells. Nat Protoc (2008) 3(9):1402-13. doi:10.1038/nprot.2008.120
46. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, et al. HMDB: the human metabolome database. Nucleic Acids Res (2007) 35(Database issue):D521-6. doi:10.1093/nar/gkl923
47. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 457(7231):910-4. doi:10.1038/nature07762
48. Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European prospective investigation into cancer and nutrition study. Am J Clin Nutr (2007) 86(3):672-81. doi:10.1093/ajcn/86.3.672
49. Nyman DW, Suzanne Stratton M, Kopplin MJ, Dalkin BL, Nagle RB, Jay Gandolfi A. Selenium and selenomethionine levels in prostate cancer patients. Cancer Detect Prev (2004) 28(1):8-16. doi:10.1016/j.cdp.2003.11.002
50. Sekihara H. 19-Hydroxyandrostenedione: evidence for a new class of sodium-retaining and hypertensinogenic steroids. Endocrinology (1983) 113(3):1141-8. doi:10.1210/endo-113-3-1141
51. Sekihara H. 19-Hydroxyandrostenedione: a potent hypertensinogenic steroid in man. J Steroid Biochem (1983) 19(1A):353-8. doi:10.1016/S0022-4731(83)80047-8
52. Sekihara H. Evidence that 19-hydroxyandrostenedione is secreted by the adrenal cortex and is under the control of ACTH and the renin-angiotensin system in man. Biochem Biophys Res Commun (1982) 105(2):610-4. doi:10.1016/0006-291X(82)91478-4
53. Tosha T, Kagawa N, Ohta T, Yoshioka S, Waterman MR, Kitagawa T. Raman evidence for specific substrate-induced structural changes in the heme pocket of human cytochrome P450 aromatase during the three consecutive oxygen activation steps. Biochemistry (2006) 45(17):5631-40. doi:10.1021/bi060094a
54. Raeside JI, Renaud RL, Friendship RM, Khalil MW. Secretion of 19-hydroxyandrostenedione and 19-hydroxytestosterone by porcine Leydig cells in vitro and in vivo. J Endocrinol (1993) 137(2):281-9. doi:10.1677/joe.0.1370281
55. Norton BI, Miyairi S, Fishman J. 19-Hydroxylation of androgens by rat granulosa cells. Endocrinology (1988) 122(3):1047-52. doi:10.1210/endo-122-3-1047
56. McDunn JE, Li Z, Adam KP, Neri BP, Wolfert RL, Milburn MV, et al. Metabolomic signatures of aggressive prostate cancer. Prostate (2013) 73(14):1547-60. doi:10.1002/pros.22704
57. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem (2007) 102(4):899-911. doi:10.1002/jcb.21529
58. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J (2008) 22(5):1512-20. doi:10.1096/fj.07-9526com
59. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 68(11):4447-54. doi:10.1158/0008-5472.CAN-08-0249
60. Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate (2005) 63(1):29-43. doi:10.1002/pros.20155
61. Fixemer T, Remberger K, Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate (2002) 53(2):118-23. doi:10.1002/pros.10133
62. Huang J, Yao JL, di Sant'Agnese PA, Yang Q, Bourne PA, Na Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate (2006) 66(13):1399-406. doi:10.1002/pros.20434
63. Verhagen AP, Aalders TW, Ramaekers FC, Debruyne FM, Schalken JA. Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate (1988) 13(1):25-38. doi:10.1002/pros.2990130104
64. Mariot P, Vanoverberghe K, Lalevee N, Rossier MF, Prevarskaya N. Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J Biol Chem (2002) 277(13):10824-33. doi:10.1074/jbc.M108754200
65. Starka L. Epitestosterone. J Steroid Biochem Mol Biol (2003) 87(1):27-34. doi:10.1016/S0960-0760(03)00383-2
66. Chang KH, Ercole CE, Sharifi N. Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences. Br J Cancer (2014) 111(7):1249-54. doi:10.1038/bjc.2014.268
67. Harkonen P, Torn S, Kurkela R, Porvari K, Pulkka A, Lindfors A, et al. Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state. J Clin Endocrinol Metab (2003) 88(2):705-12. doi:10.1210/jc.2002-020236
68. Fishman J, Goto J. Mechanism of estrogen biosynthesis. Participation of multiple enzyme sites in placental aromatase hydroxylations. J Biol Chem (1981) 256(9):4466-71
69. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res (2007) 42(1):28-42. doi:10.1111/j.1600-079X.2006.00407.x
70. Ximenes VF, Catalani LH, Campa A. Oxidation of melatonin and tryptophan by an HRP cycle involving compound III. Biochem Biophys Res Commun (2001) 287(1):130-4. doi:10.1006/bbrc.2001.5557
71. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature (2011) 478(7368):197-203. doi:10.1038/nature10491
72. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med (2016) 22(3):298-305. doi:10.1038/nm.4045
73. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 2(5):401-4. doi:10.1158/2159-8290.CD-12-0095
74. Charlesworth MC, Young CY, Miller VM, Tindall DJ. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. J Androl (1999) 20(2):220-9
75. Raj GV, Barki-Harrington L, Kue PF, Daaka Y. Guanosine phosphate binding protein coupled receptors in prostate cancer: a review. J Urol (2002) 167(3):1458-63. doi:10.1016/S0022-5347(05)65345-1
76. Blaner WS. Cellular metabolism and actions of 13-cis-retinoic acid. J Am Acad Dermatol (2001) 45(5):S129-35. doi:10.1067/mjd.2001.113714
77. Kalhan SC, Hanson RW. Resurgence of serine: an often neglected but indispensable amino Acid. J Biol Chem (2012) 287(24):19786-91. doi:10.1074/jbc.R112.357194
78. Isgro MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Adv Exp Med Biol (2015) 867:125-43. doi:10.1007/978-94-017-7215-0_9
79. Whitehead MC, Marangos PJ, Connolly SM, Morest DK. Synapse formation is related to the onset of neuron-specific enolase immunoreactivity in the avian auditory and vestibular systems. Dev Neurosci (1982) 5(4):298-307. doi:10.1159/000112689
80. Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci (1987) 10:269-95. doi:10.1146/annurev.ne.10.030187.001413
81. Cerasuolo M, Paris D, Iannotti FA, Melck D, Verde R, Mazzarella E, et al. Neuroendocrine transdifferentiation in human prostate cancer cells: an integrated approach. Cancer Res (2015) 75(15):2975-86. doi:10.1158/0008-5472.CAN-14-3830
82. Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, et al. Targeting Stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab (2016) 24(5):685-700. doi:10.1016/j.cmet.2016.10.011
83. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer (2007) 14(3):531-47. doi:10.1677/ERC-07-0061
84. di Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol (1992) 23(3):287-96. doi:10.1016/0046-8177(92)90110-O